Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.39 |
| ▸ | SRC | P12931 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.37 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 2/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.36 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17967210 | 0.75 | ALDH1A1 (0.45) | ALDH1A1MEN1KMT2AATMFFAR1 | |
| SCHEMBL19793302 | 0.75 | POLB (0.46) | ALDH1A1MEN1KMT2AATMSRC | |
| SCHEMBL17967124 | 0.75 | ALDH1A1 (0.72) | ALDH1A1MEN1KMT2AATMLMNA | |
| SCHEMBL17967116 | 0.73 | FFAR1 (0.52) | FFAR1SRCHDAC1HDAC6ENPP2 | |
| SCHEMBL18003902 | 0.73 | MGAM (0.55) | ALDH1A1MEN1KMT2ALMNAHDAC1 | |
| SCHEMBL17967183 | 0.72 | FFAR1 (0.48) | ALDH1A1MEN1KMT2AFFAR1SRC | |
| SCHEMBL17967254 | 0.72 | TDP1 (0.45) | ALDH1A1MEN1KMT2AATMFFAR1 | |
| SCHEMBL8772467 | 0.69 | HSD17B10 (0.73) | ALDH1A1LMNATAAR1 | |
| SCHEMBL17967149 | 0.69 | FFAR1 (0.48) | ALDH1A1MEN1KMT2AFFAR1SRC | |
| SCHEMBL2135113 | 0.67 | TAAR1 (0.68) | LMNATAAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180022742-A1 | AUTOTAXIN INHIBITORS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2018-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180022742-A1 | AUTOTAXIN INHIBITORS | ENPP2, RNASE1, ATXN10 | ALDH1A1 4116/4885MEN1 1121/4885KMT2A 353/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.